Who we are
The IFMRS is an international, non-profit federation of musculoskeletal research societies. Our mission is to advance musculoskeletal research globally in order to prevent and treat musculoskeletal diseases by collaborating with international societies to share resources, raise public awareness and provide education.
Leadership - IFMRS Board of Directors
Roland Baron
IFMRS Co-Chair
Bente Langdahl
IFMRS Co-Chair
D. Rick Sumner
IFMRS Treasurer
Nicola Napoli
The American Society for Bone and Mineral Research (ASBMR)
Gudrun Stenbeck
European Calcified Tissue Society (ECTS)
Mark Forwood
The Australia and New Zealand Bone and Mineral Society (ANZBMS)
Ling Qin
International Chinese Musculoskeletal Research Society (ICMRS)
Seiji Fukumoto
Japanese Society for Bone and Mineral Research (JSBMR)
Jennifer Westondorf
Orthopaedic Research Society (ORS)
Juan Jose Scali
The Iberoamerican Society of Osteology and Mineral Metabolism (SIBOMM)
Lucas Brun
Asociación Argentina de Osteología y Metabolismo Mineral (AAOMM)
Egon Perilli
Australian and New Zealand Orthopaedic Research Society (ANZORS)
Rob Daly
Australian & New Zealand Society for Sarcopenia & Frailty Research (ANZSSFR)
Bram van der Eerden
The International Bone Marrow Adiposity Society (BAMS)
Claire Edwards
Cancer and Bone Society (CABS)
Pia Eiken
Danish Bone Society (DKS)
Ralph Müller
International Society of Bone Morphometry (ISBM)
Robert Blank
The International Society for Clinical Densitometry (ISCD)
Masaru Ishii
Japanese Society for Osteoimmunology (JSO)
Yumie Rhee
Korean Society for Bone and Mineral Research (KSBMR)
Scott Byrne
Molecular & Experimental Pathology Society of Australasia (MEPSA)
Manuel Naves Díaz
Sociedad Española de Investigación Ósea y Metabolismo Mineral (SEIOMM)
Corporate Partners
We are grateful to our Gold and Silver Corporate Partners:
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
WEBSITE
Kyowa Kirin is an R&D-based life sciences company with special strengths in biotechnology. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
WEBSITE
Ipsen is a leading global biopharmaceutical company focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Active in the rare diseases field for many years, Ipsen brings scientific advancements to patients and invests significantly in R&D, leveraging global expertise and a local presence. Ipsen is committed to making innovative new treatments available to people living with rare diseases.
UCB’s ambition is to transform the lives of people living with severe diseases. Keeping patients at the center of their work and driven by science, UCB focuses on neurology and immunology disorders. UCB is continuously working to advance science and embrace new knowledge by leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology.
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare and disabling genetic condition in which skeletal muscle and connective tissue, such as tendons and ligaments, are gradually replaced by bone. This independent educational program aims to raise awareness and highlight the advances being made which have the potential to change the outlook for people with FOP.
IFMRS Committees and Working Groups
Big Data Core Group
Lynda Bonewald (ASBMR) – Chair
Jane Lian (ASBMR)
Doug Kiel (ASBMR)
David Karasik (ASBMR)
Jen Westendorf (ORS)
Farooq Rai (ORS)
Jonathan Tobias (ECTS)
Kyoung-Min Kim (KSBMR)
Qing Wu (ICMRS)
Yuuki Imai (JSBMR)
John Kemp (ANZBMS)
Keishi Fujio (JSO)
Co-opted:
Carolina Medina Gomez (ECTS)
Frank Rauch (ICCBH)
Hakan Nero (OARSI)
Future Global Leaders Core Group
Karl Lewis (ORS) – Chair
Katharina Jähn-Rickert (ECTS)
Elisabeth Winter (ECTS)
Julie Rhoades (CABS)
Erica Scheller (BMAS)
Meghan McGee-Lawrence (ASBMR)
David Scott (ANZSSFR)
Jie Shen (ICMRS)
Kazuo Okamoto (JSO)
Toshihide Mizoguchi (JSBMR)
Sabashini Ramchand (ANZBMS)
Josh Lewis (ANZBMS)
Co-opted:
Celia Gregson – SAMSON rep (SAMSON)
Alex Ireland (ICCBH)
Benny Antony (OARSI)
International Education Core Group
Mark Forwood (ANZBMS) – Chair
Karl Lewis (ORS)
Gudrun Stenbeck (ECTS)
Rob Blank (ISCD)
Patricia Juarez (CABS)
Solomon Yu (ANZSSFR)
Lin Han (ICMRS)
Takeshi Miyamoto (JSO)
Yoshiya Tanaka (JSBMR)
Kenji Hata (JSBMR)
Natasha Appelman-Dijkstra (ASBMR)
Co-opted:
Kate Ward – SAMSON rep (SAMSON)
Marie-Eve Robinson (ICCBH)
Nancy Lane (OARSI)
Staff
Federico Moscogiuri
IFMRS CEO
Email: ceo@ifmrs.org
Corporate Partnership and Support
The benefits of Corporate Partnership
By supporting and working with the IFMRS, you will be collaborating with a truly international federation of world-renowned, leading societies, with a combined membership of over 18,000. The best way to do this is via Corporate Partnership.
Corporate partnerships allows the IFMRS to initiate and deliver the activities and projects in our Strategic Plan. There are three tiers of support, with a corresponding level of benefit. All corporate partners will be acknowledged according to their level of support on the IFMRS website.
LEVEL
BENEFITS
COST (1 year)
GOLD
- Logo and acknowledgement on IFMRS website, including brief description and link to partner website
- Free ad with company logo and link in all IFMRS newsletters
- Quarterly virtual meetings with the CEO, including face-to-face at international conferences where possible.
$30,000
SILVER
- Logo and acknowledgement on IFMRS website, including brief description
- Company logo and link in all IFMRS newsletters
- Quarterly virtual meetings with the CEO, including face-to-face at international conferences where possible.
$20,000
BRONZE
- Logo and acknowledgement on IFMRS website, including brief description
- Quarterly virtual meetings with the CEO, including face-to-face at international conferences where possible.
$5,000
Please contact the ceo, Federico Moscogiuri, to discuss Corporate Partnership and other support opportunities.
Corporate Partnership Policy PDF
Click to download